Table 1.
Baseline patient characteristics (N=134)
| Characteristics | N (%) |
|---|---|
| Median age (years [IQR]) | 55 (22–80) |
| Age (years) | |
| <65 | 111 (82.8) |
| ≥65 | 23 (17.2) |
| Sex | |
| Male | 72 (53.7) |
| Female | 62 (46.3) |
| ECOG | |
| 0–1 | 129 (96.3) |
| 2 | 5 (3.7) |
| Primary site of disease | |
| Ascending colon | 89 (66.4) |
| Descending colon | 38 (28.4) |
| Rectosigmoid | 7 (5.2) |
| Disease status | |
| Metastatic | 90 (67.2) |
| Recurrence | 44 (32.8) |
| KRAS mutation | |
| Wild | 66 (49.3) |
| Mutant | 53 (39.6) |
| Unknown | 15 (11.2) |
| BRAF V600E | |
| Wild | 72 (53.7) |
| Mutant | 4 (3.0) |
| Unknown | 58 (43.3) |
| No of previous systemic anticancer therapies | |
| ≤3 | 66 (49.2) |
| ≥4 | 68 (50.7) |
| Metastatic site | |
| <3 | 96 (71.6) |
| ≥3 | 38 (28.3) |
| Previous anti-VEGF treatment (bevacizumab) | 116 (86.6) |
| Previous anti-EGFR treatment (cetuximab) | 55 (41.0) |
Abbreviation: ECOG, Eastern Cooperative Oncology Group.